• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Neurocrine Biosciences (NBIX)

Common Shares
Sell: $145.00|Buy: $149.88|Change: 0.28 (-0.19%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Address

12780 El Camino Real
San Diego
CA
USA
92130

Telephone

+1 858 6177600

Website

https://www.neurocrine.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Neurocrine Biosciences Inc Second Quarter Earnings Conference Call for 20272027-07-30T16:30:00
Neurocrine Biosciences Inc Second Quarter Earnings Results for 20272027-07-30T00:00:00
Neurocrine Biosciences Inc Annual General Meeting for 20272027-05-27T10:30:00
Neurocrine Biosciences Inc First Quarter Earnings Conference Call for 20272027-05-05T16:30:00
Neurocrine Biosciences Inc First Quarter Earnings Results for 20272027-05-05T16:00:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call for 20262027-02-11T16:30:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Results for 20262027-02-11T16:00:00
Neurocrine Biosciences Inc Annual Report for 20262027-02-11T00:00:00
Neurocrine Biosciences Inc Third Quarter Earnings Conference Call for 20262026-11-02T16:30:00
Neurocrine Biosciences Inc Third Quarter Earnings Results for 20262026-11-02T16:00:00
Academy of Managed Care Pharmacy Nexus 2026 conference2026-10-26T00:00:00

Previous key dates

NameKey Date
Academy of Managed Care Pharmacy Nexus 2026 conference2026-10-26T00:00:00
Neurocrine Biosciences Inc Second Quarter Earnings Conference Call for 20262026-07-30T16:30:00
Neurocrine Biosciences Inc Second Quarter Earnings Result for 20262026-07-30T00:00:00
Goldman Sachs 47th Annual Global Healthcare Conference 20262026-06-09T09:20:00
William Blair 46th Annual Growth Stock Conference2026-06-02T11:40:00
Neurocrine Biosciences Inc Annual General Meeting for 20262026-05-27T10:30:00
Neurocrine Biosciences Inc First Quarter Earnings Conference Call for 20262026-05-05T16:30:00
Neurocrine Biosciences Inc First Quarter Earnings Results for 20262026-05-05T16:00:00
Bank of America Health Care Conference 20262026-05-05T11:20:00
Stifel 2026 Virtual CNS Forum2026-03-17T16:30:00
Leerink Global Healthcare Conference2026-03-09T08:40:00
TD Cowen 46th Annual Health Care Conference.2026-03-03T11:50:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call for 20252026-02-11T16:30:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Results for 20252026-02-11T16:00:00
Neurocrine Biosciences Inc Annual Report for 20252026-02-11T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-12T09:45:00
R&D Day2025-12-16T12:00:00
Neurocrine Biosciences Inc Third Quarter Earnings Conference Call for 20252025-10-28T16:30:00
Neurocrine Biosciences Inc Third Quarter Earnings Results for 20252025-10-28T16:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.